Navigation Links
PLC Systems Provides Update on Japanese Approval Process for RenalGuard®
Date:1/5/2012

MILFORD, Mass., Jan. 5, 2012 /PRNewswire/ -- PLC Systems Inc. (OTC: PLCSF), a company focused on innovative medical device technologies, announced today that Dr. Ichiro Michishita, a leading Japanese cardiologist, has successfully completed two cases utilizing RenalGuard® for the prevention of Contrast-Induced Nephropathy (CIN) at Yokohama Sakae Kyosai Hospital, Yokohama, Japan. This is the first step in the process to secure regulatory approval for RenalGuard in Japan.

Dr. Michishita, Director of the hospital's Cardiovascular Division, a leading Japanese expert in CIN prevention, has worked with the Japanese Ministry of Health, Labor and Welfare (MHLW) to outline a process for RenalGuard evaluation and approval in Japan. The first step, now completed, was the initial experience of two patients.  Dr. Michishita will meet with the Ministry in February to present these findings and request approval for the previously-agreed upon 60 patient study that could begin as early as April 2012 with Dr. Naoto Inoue, who is the director of Cardiovascular Center of Sendai Kousei Hospital, as the co-investigator.  The investigators expect to complete that study within 8-10 months.  Once the study is concluded, the results will be submitted to the MHLW, as part of a package for shonin approval from the agency.  Completion of this process, if successful, would allow the importation of RenalGuard for sales and marketing in Japan. 

Mark R. Tauscher, President and Chief Executive Officer of PLC, said, "We are absolutely delighted by the positive experience of these initial cases utilizing RenalGuard in Japan.  Dr. Michishita's leadership in CIN prevention is paving the way for the clinical study that hopefully will lead to the approval by the MHLW to allow us to begin selling RenalGuard in Japan. The Japanese market is arguably the second largest market in the world for RenalGuard, based upon the number of cath lab
'/>"/>

SOURCE PLC Systems Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
2. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
3. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
4. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
5. Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
6. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
7. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
8. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
9. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
10. PLC Systems Reports Fourth Quarter 2007 Results
11. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
(Date:5/21/2013)... Calif. , May 21, 2013 /PRNewswire/ ... ), a specialty pharmaceutical company focused on ... for the treatment of acute and breakthrough ... in a placebo-controlled Phase 3 study of ... analgesia) System (NanoTab System), the primary efficacy ...
Breaking Medicine Technology:Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
... RA Signs and Symptoms Compared to Placebo, ... (Nasdaq: TRBN ) today announced preliminary ... double-blind, placebo-controlled, multicenter,clinical trial of its TRU-015 ... indicated that Trubion,s TRU-015 product candidate, at,well-tolerated ...
... Calif., Sept. 10 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... antibodies for the treatment of cancer and,hepatitis C ... submitted a,clinical protocol with the Drug Controller General ... safety and efficacy trial of bavituximab in combination,with ...
Cached Medicine Technology:Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 2Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 3Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 4Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 5Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 2Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 3Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 4
(Date:5/20/2013)... The India Network Foundation, a ... insurance, announces a new pre-existing condition coverage plan: ... the years, India Network members have requested a ... maximums, and duration. The Platinum Comprehensive Plan is ... the valuable coverage and benefits of a PPO ...
(Date:5/20/2013)... Heritage Woods of Gurnee , ... Illinois, is hosting Breakfast and Bingo at 8:30 a.m. ... located at 3775 Grand Ave. in Gurnee, Illinois, serves ... who need some help to maintain their independence. , ... of bingo," says Tammy Temaner-Rosas, Director of Marketing for ...
(Date:5/20/2013)... May 21, 2013 For the ... the Best of Frederick Award in the Professional ... Association (USCA). , The USCA "Best of Local ... the country. Each year, the USCA identifies companies ... in their local community and business category. These ...
(Date:5/20/2013)... May 20, 2013 Recent environmental ... of using green and sustainable inputs in packaging ... implemented regulations to promote the use of sustainable ... and Labelling Services industry . “Tax subsidies and ... says IBISWorld industry analyst Deonta Smith. “For example, ...
(Date:5/20/2013)... Dr. Robert Mokbel is one of the ... the Laser Assisted New Attachment Procedure, a laser ... disease. LANAP may help many Fountain Valley residents who ... the jawbone support necessary to support dental implants. , ... tartar in the mouth. Daily oral hygiene activities typically ...
Breaking Medicine News(10 mins):Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 2Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 3Health News:Heritage Woods of Gurnee Affordable Assisted Living Community to Host Breakfast and Bingo 2Health News:A2LA Receives 2013 Best of Frederick Award 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Fountain Valley, Ca Gum Disease Patients with Missing Teeth Can Now Receive Laser Gum Surgery from Dr. Robert Mokbel for Success with Dental Implants 2
... of Minnesota scientists anti-angiogenics are compounds that are very ... molecules which cut of the blood supply to the ... The study results appear in the Journal of the ... drugs that increases the potential for good, effective treatment ...
... monitoring data human welfare, spread of infectious disease and food ... to acquire the proper balance between ecological systems//. ... has used a satellite imagery to enable the study of ... effect on human health and food security. ,Doug ...
... of Kansas State University, Doug Goodin, makes use of ... and land cover //changes on human health and food ... sensing with other types of data, to monitor and ... scientists he recently discussed this subject at the workshop, ...
... to zero in (on) the modalities of a drug, capable ... Clinical trials on animal models have revealed the capacity of ... in charge of energy production., ,'Many drugs block ... Glick, who is the Werner E. Bachmann Collegiate Professor of ...
... NHS can be freed from its’ problems, if privatization ... are implemented. // It is amply clear that the ... worse for the deprived and under privileged sections of ... low morale among Doctors and NHS staff. Quality of ...
... BARACLUDE? (entecavir) for the treatment of chronic hepatitis B ... General of India. ,BARACLUDE (entecavir) is indicated ... in adults with evidence of active viral replication and ... or AST) or histologically active disease. ,BARACLUDE? ...
Cached Medicine News:Health News:Ecological Changes affects human health, food security 2Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2Health News:Autoimmune disorders studied in detail by U-M researchers. 2Health News:India Approves Baraclude? (entecavir) For ,Treatment Of Chronic HEPATITIS B 2
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
... next generation system for ... the power of automation ... laboratory. As many as ... loaded and analyzed in ...
Medicine Products: